Equillium Announces Poster Presentation at the 50th Anniversary La Jolla Immunology Conference

Equillium sees potential for EQ504 to address both barrier dysfunction and inflammation in ulcerative colitis.

Rhea-AI Summary

Equillium (EQ) will present new EQ504 preclinical data at the La Jolla Immunology Conference on October 6, 2026.

In an intestinal co-culture model, which studies intestinal cells together, EQ504 preserved barrier integrity while suppressing inflammatory cytokine production, or immune signaling proteins. The company said these findings support EQ504’s potential to address barrier dysfunction and inflammation in ulcerative colitis. Poster I-37 is scheduled for 11:00am to 1:00pm PT.

Positive

• Minor pointEQ504 preclinical findings showed preserved barrier integrity and suppressed inflammatory cytokine production in an intestinal co-culture model.

Negative

• None.

Key Terms

ahr, co-culture model, cytokine, ulcerative colitis

4 terms

ahr medical

"AhR activation stabilizes inflammatory crosstalk"

AHR, short for the aryl hydrocarbon receptor, is a protein inside cells that acts like a sensor or thermostat for certain environmental chemicals and signals, turning on or off specific genes in response. Investors care because AHR can influence how drugs are processed, how the immune system reacts, and whether a therapy has safety or effectiveness issues—making it a key factor in drug development, regulatory approval and commercial prospects.

co-culture model technical

"in an intestinal co-culture model"

A co-culture model is a laboratory system in which two or more different cell types are grown together so they can interact, allowing researchers to study cell-to-cell communication, signaling, immune responses, or tissue-like behavior that does not appear when each cell type is grown alone. Co-cultures can be simple (two cell types mixed in the same dish) or structured (separate compartments, layered cells, or three-dimensional scaffolds), and they are used to replicate aspects of a real tissue or microenvironment; however, they remain simplified models that may not capture the full complexity of living organs or whole organisms.

cytokine medical

"suppressing inflammatory cytokine production"

Small proteins produced by cells that act as chemical messengers to coordinate immune and inflammatory responses, like text messages or traffic signals telling cells when to activate, calm down, or move. Investors care because cytokines are common drug targets and biomarkers; changes in cytokine activity can determine a therapy’s effectiveness, safety, regulatory approval, and market potential, so trial results or safety signals tied to cytokines often drive stock moves.

ulcerative colitis medical

"particularly relevant to ulcerative colitis"

A long-term inflammatory disease that causes repeated sores and irritation in the large intestine, leading to symptoms such as abdominal pain, urgent diarrhea, and fatigue. For investors, it matters because the condition creates a steady need for effective treatments, influences the size of drug and medical-device markets, and makes clinical trial results, regulatory decisions and treatment approvals material to companies’ revenue prospects—like watching for fixes to a recurring leak in an important building system.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

New preclinical data further characterizes EQ504’s coordinated effects across epithelial and immune compartments in intestinal inflammation

LA JOLLA, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that new preclinical data from its EQ504 program will be presented in a poster at the 50^th Anniversary La Jolla Immunology Conference, taking place October 6-8, 2026 in La Jolla, California.

“These data provide additional insight into the multi-modal activity of EQ504, demonstrating coordinated effects across epithelial and immune compartments that preserve barrier integrity while resolving inflammation,” said Dr. Stephen Connelly, Chief Scientific Officer of Equillium. “We believe these complementary effects are particularly relevant to ulcerative colitis, where both reducing inflammation and improving mucosal healing are important to achieving meaningful outcomes for patients.”

Details of the poster presentations:

Title: AhR activation stabilizes inflammatory crosstalk and promotes barrier repair in an intestinal co-culture model
Poster Number: I-37
Lead Author: Rosa Quinn Closser
Presentation Type: Poster Session 1
Date: October 6, 2026
Time: 11:00am to 1:00pm PT
Presentation Summary: EQ504 demonstrated coordinated effects across epithelial and immune compartments in an intestinal co-culture model, preserving barrier integrity while suppressing inflammatory cytokine production. These findings further support the potential of EQ504 to address both barrier dysfunction and inflammation in ulcerative colitis.

Following the presentation, the poster will be available on the Presentations page located under the Technology section of equilliumbio.com.

About EQ504
EQ504 is an investigational potent and selective aryl hydrocarbon receptor (AhR) modulator with a multi-modal, non-immunosuppressive mechanism of action designed to be complementary to other inflammation and immunology agents. AhR is critical to barrier organ tissue physiology and immunology, maintaining barrier function and promoting tissue repair and regeneration, while regulating resident immune cells with anti-inflammatory responses. EQ504’s preclinical properties provide the potential for targeted, local delivery via enteric coating for the treatment of ulcerative colitis and other gastrointestinal diseases or inhaled formulations for the treatment of inflammatory lung diseases.

About Equillium
Equillium is a biotechnology innovator with a mission to develop highly impactful therapies to treat severe autoimmune and inflammatory disorders.

For more information, visit www.equilliumbio.com.

Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “could”, “continue”, “expect”, “estimate”, “may”, “plan”, “outlook”, “future”, “potential” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements include, but are not limited to, statements regarding Equillium’s plans and strategies with respect to developing EQ504, including the initiation of clinical studies and the reporting of data therefrom; the expected timeline for initiating and reporting data from a Phase 1 study of EQ504; and the potential benefits of EQ504. Because such statements are subject to risks and uncertainties, many of which are outside of Equillium’s control, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: Equillium’s ability to execute its plans and strategies; risks related to performing clinical and pre-clinical studies; whether the results from clinical and pre-clinical studies will validate and support the safety and efficacy of Equillium’s product candidates; changes in the competitive landscape; and Equillium’s ability to raise sufficient financing, which may not be available on acceptable terms or at all, to advance EQ504 and fund Equillium’s strategic plans. These and other risks and uncertainties are described more fully under the caption "Risk Factors" and elsewhere in Equillium's filings and reports, which may be accessed for free by visiting the Securities and Exchange Commission’s website and on Equillium’s website under the heading “Investors.” Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Investor Contact
PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Equillium’s EQ504 preclinical findings show?

EQ504 preserved barrier integrity while suppressing inflammatory cytokine production in an intestinal co-culture model. The findings demonstrated coordinated effects across epithelial cells, which form tissue barriers, and immune cells.